Results 241 to 250 of about 3,530,803 (397)

Oscillating gradient spin echo diffusion time effects implicate variations in neurite beading for the heterogeneous reduced diffusion in human acute ischemic stroke lesions

Magnetic Resonance in Medicine, Volume 94, Issue 5, Page 2158-2172, November 2025.
Abstract Purpose Monte Carlo simulations and short diffusion time measurements have suggested neurite beading and swelling as the underlying mechanism of reduced diffusion in acute stroke, although the observed diffusion time dependence is often heterogeneous and not yet fully understood.
Mi Zhou, Rob Stobbe, Matthew Budde, Brian Buck, Mahesh Kate, Mar Lloret, Paige Fairall, Ken Butcher, Ashfaq Shuaib, Derek Emery, Thorsten Feiweier, Christian Beaulieu   +11 more
wiley   +1 more source

Intravenous tissue plasminogen activator in functional stroke mimics. [PDF]

Postep Psychiatr Neurol
Kowalska MM, Michałowska MM, Leńska-Mieciek MM.   +2 more
europepmc   +1 more source

The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro [PDF]

, 1989
HR Lijnen, B. Van Hoef, F De Cock, D Collen   +3 more
openalex   +1 more source

Granulocyte Transfusions in Pediatric Hemato‐Oncology: Neutrophil Response and CRP Kinetics

Pediatric Blood &Cancer, Volume 72, Issue 11, November 2025.
ABSTRACT Background Granulocyte transfusions (GTXs) are used in neutropenic pediatric hemato‐oncology patients with infections unresponsive to antimicrobial therapy, but their clinical benefit remains uncertain. Methods We retrospectively reviewed all pediatric patients who received GTXs between 2013 and 2023 at a tertiary medical center.
Aviv Sever, Ron Rabinowicz, Shlomit Barzilai‐Birenboim, Salvador Fisher, Ronit Goldman Levi, Assaf Yanir, Jerry Stein, Efraim Bilavsky, Joanne Yacobovich, Vered Yahalom   +9 more
wiley   +1 more source

Hepatic AhR Activation by TCDD Induces Obesity and Steatosis via Hepatic Plasminogen Activator Inhibitor-1 (PAI-1). [PDF]

Int J Mol Sci
Oh SJ, Im S, Kang S, Lee AG, Lee BC, Pak YK.   +5 more
europepmc   +1 more source

Training bias and sequence alignments shape protein–peptide docking by AlphaFold and related methods

Protein Science, Volume 34, Issue 11, November 2025.
Abstract Protein‐peptide interactions mediate many biological processes. Accurate structural models of protein‐peptide complexes, determined by experiment or computational prediction, are essential for understanding function and designing interaction inhibitors.
Lindsey Guan, Amy E. Keating
wiley   +1 more source

Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastoma. [PDF]

J Exp Clin Cancer Res
Shifman SG, O'Connor JL, Radin DP, Sharma A, Infante L, Ferraresso F, Kastrup CJ, Lawrence DA, Tsirka SE.   +8 more
europepmc   +1 more source

Structural similarities reveal an expansive conotoxin family with a two‐finger toxin fold

Protein Science, Volume 34, Issue 11, November 2025.
Abstract Venomous animals have evolved a diverse repertoire of toxins with considerable pharmaceutical potential. The rapid evolution of peptide toxins, such as the conotoxins produced by venomous marine cone snails, often complicates efforts to infer their evolutionary relationships based solely on sequence information.
Muhammad Saad Khilji, Celeste M. Hackney, Thomas L. Koch, Arik J. Hone, Aymeric Rogalski, Maren Watkins, Jortan Tun, J. Michael McIntosh, Baldomero Olivera, Helena Safavi‐Hemami, Kaare Teilum, Lars Ellgaard   +11 more
wiley   +1 more source

Tissue Plasminogen Activator to Resolve Elevated Purge System Pressure in a Catheter-Based Ventricular Assist Device. [PDF]

JACC Case Rep
Khattak S, Shamkhani W, Maqableh GM, Al-Shatanawi A, Khan SQ.   +4 more
europepmc   +1 more source

Blockade of cannabinoid CB1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy

British Journal of Pharmacology, Volume 182, Issue 21, Page 5355-5377, November 2025.
Background and purpose Diabetic nephropathy (DN) is a common complication of diabetes. Current treatments include renin‐angiotensin‐aldosterone system (RAAS) blockers and sodium‐glucose co‐transporter 2 (SGLT2) inhibitors. The cannabinoid CB1 receptor is a potential therapeutic target.
Océane Pointeau, Awa Isma Ba, Audrey Geissler, Romain Barbosa, Abhishek Basu, Arif Muhammad, Marina Nivot, Maéva Loriot, Julia Leemput, Patricia Passilly‐Degrace, Sébastien Causse, Laurent Demizieux, Hélène François, Bruno Vergès, Jianmin Duan, Geneviève Gaucher, Michael Harvey, Pascal Degrace, Glenn Crater, Resat Cinar, Tony Jourdan   +20 more
wiley   +1 more source